Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

August 07, 2023 08:00 ET | Source: MBX Biosciences, Inc.

MBX Biosciences Announces U.S. FDA Clearance of IND Application for MBX 1416 for the Treatment of Post-Bariatric Hypoglycemia

CARMEL, Ind., Aug. 07, 2023 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc., a clinical stage biopharmaceutical company developing Precision Endocrine Peptide™ (PEP™) therapeutics to treat an array of...
July 10, 2023 08:00 ET | Source: MBX Biosciences, Inc.

MBX Biosciences Appoints Steven J. Prestrelski, Ph.D., M.B.A., as Chief Scientific Officer

CARMEL, Ind., July 10, 2023 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc., a clinical stage biopharmaceutical company developing Precision Endocrine Peptide™ (PEP™) therapeutics to treat an array of...
May 24, 2023 08:00 ET | Source: MBX Biosciences, Inc.

MBX Biosciences to Participate in Jefferies Healthcare Conference

CARMEL, Ind., May 24, 2023 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc., a clinical stage biopharmaceutical company developing Precision Endocrine Peptide™ (PEP™) therapeutics to treat an array of...
May 08, 2023 08:00 ET | Source: MBX Biosciences, Inc.

MBX Biosciences to Participate in May Investor Conferences

CARMEL, Ind., May 08, 2023 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc., a clinical stage biopharmaceutical company developing Precision Endocrine Peptide™ (PEP™) therapeutics to treat an array of...
April 10, 2023 08:00 ET | Source: MBX Biosciences, Inc.

MBX Biosciences to Participate in the Needham 22nd Annual Healthcare Conference

CARMEL, Ind., April 10, 2023 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc., a clinical stage biopharmaceutical company developing Precision Endocrine Peptide™ (PEP™) therapeutics to treat an array of...
March 07, 2023 08:00 ET | Source: MBX Biosciences, Inc.

MBX Biosciences to Participate in the Oppenheimer 33rd Annual Healthcare Conference

CARMEL, Ind., March 07, 2023 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc., a clinical stage biopharmaceutical company developing Precision Endocrine Peptide™ (PEP™) therapeutics to treat an array of...
January 24, 2023 08:00 ET | Source: MBX Biosciences, Inc.

MBX Biosciences to Participate in the SVB Securities Global Biopharma Conference

CARMEL, Ind., Jan. 24, 2023 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc., a clinical stage biopharmaceutical company developing Precision Endocrine Peptide™ (PEP™) therapeutics to treat an array of...
January 05, 2023 08:00 ET | Source: MBX Biosciences, Inc.

MBX Biosciences to Present at the 41st Annual J.P. Morgan Healthcare Conference

CARMEL, Ind., Jan. 05, 2023 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc., a clinical stage biopharmaceutical company developing Precision Endocrine Peptide™ (PEP™) therapeutics to treat an array of...
November 14, 2022 08:00 ET | Source: MBX Biosciences, Inc.

MBX Biosciences Closes $115 Million Series B Financing to Advance Development of Endocrine Disease Programs

CARMEL, Ind., Nov. 14, 2022 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc., a clinical stage biopharmaceutical company developing Precision Endocrine Peptide™ (PEP™) therapeutics to treat an array of...
October 05, 2022 09:00 ET | Source: MBX Biosciences, Inc.

MBX Biosciences Advances Phase 1 Clinical Trial of Long-Acting Parathyroid Hormone Peptide Prodrug, MBX 2109

CARMEL, Ind., Oct. 05, 2022 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc., a clinical stage biopharmaceutical company developing Precision Endocrine Peptide™ (PEP™) therapeutics to treat an array of...